Picard Medical underwriters exercise full over-allotment option

Picard Medical, Inc. (NYSE American: PMI) announced that underwriters of its initial public offering exercised their over-allotment option in full on September 5, 2025, according to a company statement.

The exercise resulted in the issuance of an additional 637,500 shares of common stock at $4.00 per share, generating gross proceeds of $2.55 million before deducting underwriting discounts and estimated offering expenses.

The company's shares began trading on the NYSE American under the ticker symbol "PMI" on August 29, 2025. WestPark Capital, Inc. served as lead manager and sole bookrunner for the offering, with Sentinel Brokers Co., Inc. as co-manager.

The Securities and Exchange Commission declared the registration statement for these securities effective on August 12, 2025.

Picard Medical is the parent company of SynCardia Systems, LLC, which develops the SynCardia Total Artificial Heart. The company states this is the only commercially available total artificial heart technology for patients with end-stage heart failure in the United States and Canada. The device has received approval from both the FDA and Health Canada.

According to the company, more than 2,100 implants have been performed at hospitals across 27 countries. SynCardia Systems is based in Tucson, Arizona.

You May Also Be Interested In

• CalciMedica raises up to $49M in private placement for PH program
• ROC to acquire digital forensics firm ZTC for up to $3M
• Hyperscale Data signs $1.2B AI compute deal for Michigan campus